Perrigo Company plc Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Perrigo Company plc on October 22, 2015. The filing primarily announces the release of earnings for the third calendar quarter of 2015, significant corporate governance changes, and the initiation of strategic initiatives including a share repurchase program.
Key Financial Metrics and Non-GAAP Adjustments
The filing references an attached earnings release (Exhibit 99.1) for specific GAAP financial figures but does not list the raw revenue, profit, or cash flow numbers within the text of this 8-K. Instead, it details the non-GAAP adjustments management uses to evaluate core performance:
- Excluded Items (Q3 2015): Amortization of acquired intangibles, restructuring charges, acquisition/integration costs, equity method investment losses, legal/consulting fees related to the Mylan N.V. defense, and losses related to the euro-denominated purchase price of the GSK product portfolio.
- Excluded Items (Q3 2014): Similar items including amortization, restructuring, acquisition costs, equity losses, and investment distributions.
- Reconciliation: The company provides reconciliations for organic sales, gross profit, operating income, and net income to GAAP measures in the attached press release.
Material Changes and Strategic Initiatives
On October 22, 2015, the Company announced several material strategic actions:
- Share Repurchase: Authorization of a $2.0 billion share repurchase plan to be executed over three years.
- Operational Restructuring: Initiatives to globalize the supply chain via shared services, streamline organizational structure for efficiency, and commence a strategic alternatives process for certain assets.
- Leadership Changes: John T. Hendrickson was promoted from Executive Vice President, Global Operations and Supply Chain, to President. Joe Papa stepped down as President but continues as Chairman and CEO.
Guidance, Outlook, and Risks
Guidance: Non-GAAP guidance for the full calendar year 2015 excludes restructuring, unusual litigation charges, costs associated with the unsolicited Mylan offer, and costs related to the newly announced initiatives. The filing states that a reconciliation to GAAP for the full year is currently impracticable due to the uncertainty and variability of these items.
Risks and Contingencies:
- Mylan Offer: Significant uncertainty remains regarding future actions by Mylan N.V. in furtherance of its unsolicited acquisition offer.
- Execution Risk: Risks associated with the timing, amount, and cost of share repurchases, as well as the ability to achieve desired benefits from the announced operational initiatives.
- Forward-Looking Statements: The filing includes standard disclaimers that actual results may differ materially from projections due to known and unknown risks.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q3 2015 GAAP revenue, net income, and earnings per share figures.
- Verify the reconciliation tables in Exhibit 99.1 to understand the magnitude of the non-GAAP adjustments, particularly the Mylan defense costs and GSK acquisition losses.
- Monitor the progress of the strategic alternatives process for certain assets and the timeline for the $2.0 billion share repurchase.
- Assess the impact of the Mylan N.V. unsolicited offer on the company's ability to execute its long-term strategy.